Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Intercellular Mediator, Neurotransmitter, Or Fragment Thereof Patents (Class 424/198.1)
-
Patent number: 8932603Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: February 25, 2004Date of Patent: January 13, 2015Assignee: Vaccibody ASInventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
-
Patent number: 8926983Abstract: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular antigenic constructs generally comprising a peptide sequence, covalently attached to pegylated lysine resulting in modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and can ultimately be employed in therapeutic formulations and vaccines for diseases and disorders such as Alzheimer's disease.Type: GrantFiled: February 22, 2005Date of Patent: January 6, 2015Assignee: AC Immune SAInventors: Yves Claude Nicolau, Ruth Greferath, David Hickman
-
Patent number: 8900593Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).Type: GrantFiled: January 9, 2013Date of Patent: December 2, 2014Assignee: Indiana University Research and Technology CorporationInventors: Jonathan Day, James Patterson, Joseph Chabenne, Maria DiMarchi, David L. Smiley, Richard D. DiMarchi
-
Patent number: 8883724Abstract: Application of oligonucleotide and polypeptide sequences of molecules of the family of the vascular permeability factor (VPF), their receptors, and co-receptors, as well as their modifications, in the active immunotherapy of pathologic entities in which course is associated to the increase of angiogenesis. These procedures can be employed in the single or combined therapy for the treatment of cancer and its metastasis, acute and chronic inflammatory processes, infectious diseases, autoimmune diseases, diabetic and newborn retinopathies, organ transplant rejection, macular degeneration, neovascular glaucoma, hemangioma, and angiofibroma, among others.Type: GrantFiled: November 4, 2009Date of Patent: November 11, 2014Assignee: Centro de Ingenieria Genética y BiotecnologiaInventors: Mónica Bequet Romero, Boris Ernesto Acevedo Castro, Jorge Victor Gavilondo Cowley, Luis Enrique Fernández Molina, Omar Lopez Ocejo, Ricardo de la Caridad Silva Rodriguez, Alexis Musachio Lasa, Ernesto Galban Rodriguez, Dania Marcia Vásquez Blomquist
-
Publication number: 20140294889Abstract: The present invention relates to the use of the pituitary adenylate cyclase activating peptide (PACAP) as a molecular adjuvant for vaccines. Among other applications, these vaccines may be used in the protection against infectious agents such as viruses, bacteria and ectoparasites affecting mammals, birds and aquatic organisms. The PACAP, combined with a particular antigen, demonstrates its effectiveness as adjuvant increasing the host immune response against that antigen. This type of response can be observed when the vaccine compositions or combinations that include PACAP are administered orally, by injection, or by immersion baths, in case of aquatic organisms.Type: ApplicationFiled: August 24, 2012Publication date: October 2, 2014Applicant: Centro De Ingenieria Genetica y BiotecnologiaInventors: Juana Maria Lugo Gonzalez, Yamila Carpio Gonzalez, Mario Pablo Estrada Garcia
-
Patent number: 8846308Abstract: Methods of identifying immune response modulators are disclosed. Some methods comprise identifying chemical candidates that modulate oligomerization of FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate the hetero-oligomerization of FOXP1 with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate interaction of IL-2 promoter with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Method of treating individuals who have or are suspected of having autoimmune disease, inflammatory disease, cell, tissue or organ transplantation, or coronary artery disease, and methods of treating individuals who have or are suspected of having infectious disease, cancer, or who are immunocompromised or undergoing vaccination are disclosed.Type: GrantFiled: June 6, 2008Date of Patent: September 30, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Bin Li
-
Patent number: 8840877Abstract: Method for preparing an oxidized polysaccharide-protein composition, by (a) oxidizing a polysaccharide with an oxidizing agent to form an oxidized polysaccharide where less than 20% of the oxidized units are comprised of alpha-hydroxy aldehyde units, (b) reacting the oxidized polysaccharide with a protein to form a composition comprising an oxidized polysaccharide-protein conjugate, and (c) maintaining the oxidized polysaccharide-protein conjugate composition by placing it in an environment where the temperature is less than 8° C. The oxidized polysaccharide and the protein are conjugated via one or more imine bonds, the oxidized polysaccharide-protein composition is soluble in aqueous solvent, and the composition is capable of releasing the protein.Type: GrantFiled: June 26, 2009Date of Patent: September 23, 2014Assignee: Therapure Biopharma Inc.Inventors: Gord Adamson, David Bell, Steven Brookes
-
Patent number: 8828723Abstract: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response.Type: GrantFiled: February 26, 2013Date of Patent: September 9, 2014Assignee: Taiga Biotechnologies, Inc.Inventors: Yosef Refaeli, Brian Curtis Turner
-
Publication number: 20140248211Abstract: The invention provides a method for treating cancer using a coadministration strategy that combines local codelivery of a therapeutic agent and an intracellular penetration enhancing agent, and optionally in further combination with local administration of an immunotherapeutic agent, such as a cancer vaccine or NKT agonist. The invention also provides a method for treating cancer using an intracellular penetration enhancing agent. The methods of the invention aim to substantially kill and/or destroy the target tumor cells, as well as those cancerous cells that have metastasized to other parts of the body.Type: ApplicationFiled: May 16, 2014Publication date: September 4, 2014Applicant: INTENSITY THERAPEUTICS, INC.Inventor: Lewis H. Bender
-
Publication number: 20140234423Abstract: Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation. The compositions and methods are useful to reduce the severity of autoimmunity, chronic inflammation, allergy, and periodontal disease.Type: ApplicationFiled: February 20, 2014Publication date: August 21, 2014Applicants: FORSYTH DENTAL INFIRMARY FOR CHILDREN, PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Roger Warren Sands, Eduardo Alexandre Barros e Silva, Toshihisa Kawai, David J. Mooney
-
Patent number: 8795672Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a liver-expressed chemokine (LEC). In one embodiment, the cancer targeting molecule is an antibody that targets cancer cells or tumors in vivo. The cancer targeting molecule is associated non-covalently or covalently with LEC. The cancer therapeutic agents of the invention are useful for the treatment of cancer in an individual by reducing the size of a tumor or inhibiting the growth of cancer cells in an individual and/or by inhibiting the development of metastasis. The effectiveness of the therapy using the LEC cancer therapeutic agents can be increased by reducing the activity of immunoregulatory T cells and/or by adoptively transferring immune T cells.Type: GrantFiled: February 13, 2004Date of Patent: August 5, 2014Assignee: University of Southern CaliforniaInventors: Alan L. Epstein, Jiali Li, Peisheng Hu
-
Publication number: 20140178400Abstract: The present invention relates to compositions and methods for modulation of TH17 responses. The invention provides compositions for the induction of TH17 responses containing a TLR agonist and an apoptotic cell-associated agent or containing a microbe-infected apoptotic cell. The compositions of the present invention may also contain dendritic cells capable of inducing TH17 responses. In other embodiments, the invention provides compositions for the inhibition of TH17 responses containing one or more blocking agents. Methods and compositions for the modulation of TH17 responses and for the treatment of TH17-associated diseases and for cancer are also provided.Type: ApplicationFiled: December 13, 2013Publication date: June 26, 2014Inventors: Julie Magarian Blander, Miriam Torchinsky
-
Publication number: 20140178334Abstract: This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication.Type: ApplicationFiled: February 28, 2014Publication date: June 26, 2014Applicant: Immunovative Therapies, Ltd.Inventor: Michael Har-Noy
-
Patent number: 8758770Abstract: Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described.Type: GrantFiled: October 4, 2010Date of Patent: June 24, 2014Assignee: Research Development FoundationInventor: Staley A. Brod
-
Patent number: 8673851Abstract: The present invention identifies that glomeruli express many neuron-specific and especially synapse-specific protein similarities. In particular, the present invention identifies Rab3A expression, including the expression of altered forms, as well as expression of other synapse-specific proteins including neurotransmitter receptors. The invention further identifies that modulation of the activity of these synapse-specific proteins results in modulation of podocytes.Type: GrantFiled: December 21, 2007Date of Patent: March 18, 2014Assignee: Fondazione d'Amico per la Ricerca Sulle Malattie RenaliInventor: Maria P. Rastaldi
-
Publication number: 20140065184Abstract: Novel use of HLA-G isoforms in the treatment or prevention of diseases in which bone resorption is observed.Type: ApplicationFiled: November 23, 2011Publication date: March 6, 2014Applicant: ETABLISSEMENT FRANCAIS DU SANGInventors: Frédéric Deschaseaux, Luc Sensebe, Nathalie Rouas-Freiss
-
Patent number: 8663650Abstract: The present invention comprises novel compositions and methods for eliciting high immune responses, of great specifity yielding conformationally sensitive antibodies. These antibodies recognize specific epitopes on a wide variety of antigens including but not limited to, amyloid protein, prion protein, P170 glycoprotein. The novel compositions of the invention comprise supramolecular antigenic constructs generally comprising a peptide sequence, covalently attached to pegylated lysine resulting in modified and enhanced peptide presentation. The unique modification methodology of the present invention is applicable to a variety of peptides and can ultimately be employed in therapeutic formulations and vaccines for diseases and disorders such as Alzheimer's disease.Type: GrantFiled: October 4, 2004Date of Patent: March 4, 2014Assignee: AC Immune SAInventors: Yves Claude Nicolau, Ruth Greferath, David Hickman
-
Patent number: 8663652Abstract: This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject a composition comprising an amount of a human stromal derived factor-1 and an amount of a human granulocyte-colony stimulating factor, the composition being administered in an amount effective to cause proliferation of cardiomyocytes within the subject's heart so as to thereby treat the disorder. This invention also provides a method of treating a subject suffering from a disorder of a tissue involving loss and/or apoptosis of cells of the tissue which comprises administering to the subject a composition comprising an amount of an agent which induces phosphorylation and/or activation of protein kinase B, or an agent which induces phosphorylation and/or activation of an extracellular signal-regulated protein kinase, or an agent which induces activation of CXCR4.Type: GrantFiled: October 23, 2003Date of Patent: March 4, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventor: Silviu Itescu
-
Publication number: 20140050741Abstract: The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.Type: ApplicationFiled: February 17, 2012Publication date: February 20, 2014Applicants: UNIVERSITEIT LEIDEN, UNIVERSITÄTSKLINIKUM FREIBURGInventors: Johannes Huebner, Andrea Huebner-Kropec, Jeroen Dirk Cornelis Codée, Gijsbert Arie Van Der Marel, Wouter Frederick Johan Hogendorf
-
Patent number: 8652488Abstract: The invention features methods for the prevention or treatment of autoimmune disorders in humans. The methods include administering an autoantigen in combination with an oil-based carrier. Included are methods for the prevention and treatment of diabetes mellitus which include treating a patient with a diabetes type 1 autoantigen, e.g., human insulin B-chain or GAD65, and an oil-based carrier approved for human use. Also included are vaccines and kits for the treatment of diabetes mellitus.Type: GrantFiled: April 13, 2006Date of Patent: February 18, 2014Assignee: Joslin Diabetes Center, Inc.Inventor: Tihamer Orban
-
Patent number: 8617532Abstract: This invention relates to use protein-polymer conjugates described in the specification to treat various diseases, including disease is idiopaic myelofibrsis, polycythaemia vera, and essential thromobocythaemia.Type: GrantFiled: December 9, 2010Date of Patent: December 31, 2013Assignee: PharmaEssentia Corp.Inventors: Ko-Chung Lin, Rudolf Widmann
-
Patent number: 8597660Abstract: Disclosed herein are isolated peptides, pharmaceutical compositions and methods for use of such for treating subjects with a neurodegenerative disease, such as Alzheimer's. In an example, an isolated polypeptide includes a cyclin dependent kinase 5 (Cdk5) inhibitory domain that has at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, wherein the Cdk5 inhibitory domain is linked to a protein transduction domain. Methods of reducing or inhibiting one or more symptoms associated with a neurodegenerative disease by administering a therapeutically effective amount of a pharmaceutical composition including one or more disclosed peptides are also provided.Type: GrantFiled: September 29, 2011Date of Patent: December 3, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Harish C. Pant, Ya-li Zheng, Niranjana D. Amin, Philip Grant, Parvathi Rudrabhatla, Varsha Shukla, Sashi Kesavapany
-
Patent number: 8591913Abstract: A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and/or a function of inducing lipolysis in the mature adipocytes.Type: GrantFiled: January 23, 2012Date of Patent: November 26, 2013Assignees: Toru Miyazaki, Dainippon Sumitomo Pharma Co., Ltd.Inventor: Toru Miyazaki
-
Publication number: 20130309267Abstract: Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer.Type: ApplicationFiled: February 11, 2011Publication date: November 21, 2013Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, BIOSANTE PHARMACEUTICALS, INC.Inventors: Andrew Simmons, Karin Jooss, James Allison
-
Patent number: 8586054Abstract: The present invention is characterized by the use of Mas-G-protein-coupled receptor agonists for the control, prevention and treatment of the body levels of triglycerides, cholesterol and glucose, as well as of hyper-tension and possible increase in body weight, which are characteristic of the clinical manifestation of the metabolic syndrome and its complications. Another characteristic of the invention is the use of Mas-G-protein-coupled receptor agonists, including the Angiotensin-(1-7) peptide and its analogs, agonists, either peptidic or non-peptidic, as modulators of the manifestations of insulin resistance and glucose intolerance and in the prevention and treatment of the related alterations.Type: GrantFiled: April 26, 2007Date of Patent: November 19, 2013Assignees: Max-Delbruck-Centrum fur Molekulare Medizin, Universidade Federal de Minas GeraisInventors: Robson Augusto Souza Dos Santos, Sergio Henrique Sousa Santos, Jaqueline Isaura Alvarez Leite, Marina Matos De Moura, Andrea Siqueira Haibara, Luciana Rodriques Fernandez, Michael Bader, Natalia Alenina, Rubens Dario Sinisterra
-
Patent number: 8568737Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: GrantFiled: August 1, 2008Date of Patent: October 29, 2013Assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, Jr., Masaru Shimizu, Fumihiko Ichikawa, Harald Juppner, Makoto Okazaki
-
Patent number: 8568736Abstract: Novel parathyroid hormone (PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: March 21, 2008Date of Patent: October 29, 2013Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald T. Juppner
-
Patent number: 8569233Abstract: Modified animal erythropoietin polypeptides and uses thereof are provide.Type: GrantFiled: July 24, 2012Date of Patent: October 29, 2013Assignees: Eli Lilly and Company, AMBRX, Inc.Inventors: Feng Tian, Anna-Maria A. Hays Putnam, Frank Song, Stephanie Chu, Joseph Sheffer, Richard S. Barnett, Marc Siladi, Kyle Atkinson, Darin Lee, Peter C. Canning
-
Patent number: 8563003Abstract: The present invention relates to methods of treatment useful in chronic diseases, by means of the rupture of tolerance to self-antigens and increasing autoimmune response against these antigens. More particularly, the present invention relates to methods useful in the treatment of tumors that are growth dependent on the Epidermal Growth Factor, including non-small cell lung carcinoma. In the present invention a therapeutic combination is revealed that includes the combination of a vaccine against self antigens with a monoclonal antibody against peripheral T cells or a chemotherapeutic drug able to induce a depletion of peripheral T cells.Type: GrantFiled: December 4, 2002Date of Patent: October 22, 2013Assignee: Centro de Inmunologia MolecularInventors: Jose Enrique Montero Casimiro, Rolando Perez Rodriguez, Agustin Bienvenido Lage Davila
-
Publication number: 20130273001Abstract: The present invention relates to an immunostimulating agent comprising at least one chemically modified RNA. The invention furthermore relates to a vaccine which comprises at least one antigen in combination with the immunostimulating agent. The immunostimulating agent according to the invention and the vaccine according to the invention are employed in particular against infectious disease or cancer diseases.Type: ApplicationFiled: March 25, 2013Publication date: October 17, 2013Inventors: Ingmar HOERR, Florlan Von Der Mulbe, Steve Pascolo
-
Patent number: 8557957Abstract: The present invention provides a compound including a peptidomimetic which interacts sterically with the binding site of a F11R molecule, the peptidomimetic including a peptidomimetic having the SEQ ID NO: 4D. The present invention also provides a method for treating a disorder comprising administering peptide 4D to a mammal.Type: GrantFiled: June 9, 2011Date of Patent: October 15, 2013Inventors: Elizabeth Kornecki, Anna Babinska, Yigal H. Ehrlich
-
Publication number: 20130259897Abstract: The invention provides crystalline forms of (R)-3-[N-(3?-chlorobiphenyl-4-ylmethyl)-N?—(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxypropionic acid isopropyl ester. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.Type: ApplicationFiled: March 27, 2013Publication date: October 3, 2013Inventors: Venkat R. Thalladi, Jerry Nzerem, Miroslav Rapta
-
Patent number: 8546324Abstract: The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In addition, the present invention relates to modified MD-2 proteins, wherein one or more tyrosine residues have been mutated to phenylalanine. In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions.Type: GrantFiled: March 18, 2011Date of Patent: October 1, 2013Assignee: Cedars-Sinai Medical CenterInventors: Moshe Arditi, Pearl Gray
-
Patent number: 8518412Abstract: The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.Type: GrantFiled: September 16, 2010Date of Patent: August 27, 2013Assignee: Senju Pharmaceutical Co, Ltd.Inventors: Takeshi Nakajima, Tomoko Nakajima, Mitsuyoshi Azuma
-
Patent number: 8518411Abstract: The invention provides modified TGF-? family proteins having altered biological or biochemical properties, and methods for making them. Specific modified protein constructs include TGF-? family member proteins that have N-terminal truncations, “latent” proteins, fusion proteins and heterodimers.Type: GrantFiled: March 7, 2007Date of Patent: August 27, 2013Assignee: Stryker CorporationInventors: Hermann Oppermann, Mei-Sheng Tai, John McCartney
-
Patent number: 8518883Abstract: A therapeutic or prophylactic treatment method of ischemia, such as due to myocardial infarction, by administering thrombopoietin, alone or in combination with other drugs, to a patient suffering from or at risk of cardiac injury, such as myocardial ischemia. The thrombopoietin is administered in a concentration such that the subject's platelet count or production of platelets is not significantly affected.Type: GrantFiled: December 17, 2010Date of Patent: August 27, 2013Assignee: MCW Research Foundation, Inc.Inventors: John E. Baker, Yang Shi
-
Publication number: 20130209505Abstract: The invention provides a crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Inventor: Miroslav RAPTA
-
Patent number: 8506965Abstract: The invention provides means and methods for vascular regulation through enhancement or inhibition of R-Ras activity. The invention specifically provides means and methods for promoting a quiescent state of a vascular cell by providing additional R-Ras activity to the cell. The invention further provides means and methods for diagnosing a condition of vasculature of an individual.Type: GrantFiled: November 11, 2005Date of Patent: August 13, 2013Assignees: Vascular BioSciences, Sanford Burnham Medical Research InstituteInventors: Masanobu Komatsu, David Marshall Mann, Erkki Ruoslahti
-
Patent number: 8501192Abstract: The invention relates to new uses of soluble CEACAM6 or CEACAM8, or substances that are specific to soluble CEACAM8. Another object of the invention concerns the use of CEACAM1-specific and/or CEACAM6-specific compounds for apoptosis prevention in-vitro. The invention also relates to a method for screening compounds, which prevent apoptosis and a method for preventing apoptosis in human granulocytes.Type: GrantFiled: September 26, 2008Date of Patent: August 6, 2013Assignee: Charite Universitaetsmedizin BerlinInventor: Bernhard Singer
-
Patent number: 8486416Abstract: A method is provided for increasing trafficking of endothelial progenitor cells to an ischemic myocardium in a subject's heart comprising administering to the subject's heart an amount of Stromal-Derived Factor-1 (SDF-1).Type: GrantFiled: January 15, 2010Date of Patent: July 16, 2013Assignee: The Trustees of Columbia University in the City of New YorkInventor: Silviu Itescu
-
Patent number: 8481049Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.Type: GrantFiled: May 18, 2006Date of Patent: July 9, 2013Assignee: Bharat Biotech International LimitedInventors: Krishna Murthy Ella, Srinivas Kannappa Vellimedu
-
Patent number: 8475766Abstract: Antibodies having dual specificity for two different but structurally related antigens are provided. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have dual specificity for IL-1? and IL-1? and neutralize IL-1? and IL-1? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting two different but structurally related antigens (e.g., IL-1? and IL-1?) and for inhibiting the activity of the antigens, e.g., in a human subject suffering from a disorder in which IL-1? and/or IL-1? activity is detrimental.Type: GrantFiled: December 11, 2008Date of Patent: July 2, 2013Assignee: AbbVie Inc.Inventors: Albert Collinson, George Avgerinos, Richard Dixon, Tariq Ghayur, Zehra Kaymakcalan
-
Patent number: 8470774Abstract: Compositions and methods for inducing the deposition of elastin in skin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.Type: GrantFiled: February 27, 2012Date of Patent: June 25, 2013Assignees: Human Matrix Sciences, LLC, The Hospital for Sick ChildrenInventors: Aleksander Hinek, Thomas F. Mitts
-
Patent number: 8466116Abstract: This disclosure provides a method of inducing epithelial cell growth. The method includes administering an effective amount of a K-type CpG oligonucleotide, thereby inducing epithelial cell growth. The epithelial cell can be in vivo or in vitro. Methods are also provided for inducing wound healing in a subject. The methods include administering to the subject a therapeutically effective amount of at least one K-type CpG ODN.Type: GrantFiled: September 5, 2008Date of Patent: June 18, 2013Assignee: The Unites States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Dennis M. Klinman, Takashi Sato
-
Patent number: 8455434Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. Also disclosed are therapeutic methods for using the cysteine variants of the invention.Type: GrantFiled: June 15, 2011Date of Patent: June 4, 2013Assignee: Bolder Biotechnology, Inc.Inventor: George N. Cox
-
Patent number: 8454971Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (K-RNRNNIA) and SEQ ID NO: 28 (KRNR).Type: GrantFiled: February 13, 2008Date of Patent: June 4, 2013Assignee: Indiana University Research and Technology CorporationInventors: Jonathan Day, James Patterson, Joseph Chabenne, Maria Dimarchi, David L. Smiley, Richard D. Dimarchi
-
Patent number: 8450288Abstract: A method for the pre-treatment of an intervertebral disc prior to the introduction of a disc prosthesis or implant includes removing at least a portion of the nucleus pulposus of the intervertebral disc to expose at least a portion of the endplate of an adjacent vertebra to the disc. A fluent treatment material is then injected into the disc space to come into contact with the portion of the endplate. The fluent treatment material is operable to prepare the portion of the endplate to accommodate a disc prosthesis, implant or graft subsequently introduced into the disc space. Different fluent treatment materials are provided that depend upon the condition of the vertebral endplates.Type: GrantFiled: February 3, 2005Date of Patent: May 28, 2013Assignee: Spine Wave, Inc.Inventor: Lawrence M. Boyd
-
Patent number: 8450274Abstract: The present invention provides DKK2 and DKK-Fc fusion protein with angiogesis promoting activity and methods of using the same.Type: GrantFiled: April 20, 2011Date of Patent: May 28, 2013Assignee: Theragenetex Co., Ltd.Inventors: Young-Guen Kwon, Jeong-Ki Min
-
Patent number: 8445000Abstract: The present invention relates to immunogenic compositions, comprising polypeptides isolated from Staphylococcus epidermidis. The invention also relates to polynucleotides encoding Staphylococcus epidermidis polypeptides and their use in immunogenic compostions. In addition, the invention relates to methods of inducing an immune response in mammals against Staphylococcus epidermidis and Staphylococcus aureus using immunogenic compostions of the Staphylococcus epidermidis polypeptides and polynucleotides. The invention also relates to methods for detecting Staphylococcus epidermidis in a biological sample.Type: GrantFiled: October 19, 2005Date of Patent: May 21, 2013Assignee: Wyeth LLCInventors: Bret Richard Sellman, Steven Morris Baker
-
Patent number: 8435949Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.Type: GrantFiled: June 11, 2012Date of Patent: May 7, 2013Assignee: Stem Cell Therapeutics Corp.Inventors: Samuel Weiss, Emeka Enwere, Linda Andersen, Christopher Gregg